Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering-Plough Targets Annual Rate Of 10 Preclinical Compounds By 2005

Executive Summary

Schering-Plough expects to move 10 compounds from discovery into preclinical development each year by 2005.

You may also be interested in...

Schering Compliance Team Will Report To CEO Following COO Resignation

Schering-Plough's compliance team for resolving FDA's Good Manufacturing Practices concerns with the company will report directly to CEO Richard Kogan following the resignation of President & Chief Operating Officer Raul Cesan.

Pfizer ACAT Inhibitor Phase III Underway; Zocor, Lipitor Prepare For Crestor

Pfizer will receive Phase III data on the anti-atherosclerotic agent avasimibe during 2001, Worldwide Development President Peter Corr told a Pfizer securities analysts meeting Dec. 11 in New York City.

Schering To Market Loratadine Metabolite As Aerius In Europe

Schering-Plough has decided on Aerius as the primary European brand name for desloratadine.

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts